[Comparative effectiveness and tolerance study of a new galenic etomidate formula]

Area of Science:

• Anesthesiology
• Pharmacology
• Formulation Science

Background:

• Etomidate is a common anesthetic induction agent.
• A major drawback of etomidate is injection pain and venous irritation.
• Novel drug delivery systems aim to improve anesthetic agent tolerability.

Purpose of the Study:

• To compare the safety and efficacy of a new lipid emulsion formulation of etomidate (Etomidat-Lipuro) against the standard propylene glycol formulation (Hypnomidate).
• To evaluate the incidence of injection pain and venous complications associated with each formulation.

Main Methods:

• Prospective, randomized, double-blind clinical trial involving 232 patients undergoing elective surgery.
• Patients received either etomidate in lipid emulsion or etomidate in propylene glycol for anesthesia induction.
• Pain and venous irritation were assessed spontaneously and through questioning post-injection.

Main Results:

• None of the patients receiving the lipid emulsion formulation reported injection pain, compared to approximately 20% in the propylene glycol group.
• The lipid emulsion formulation showed no postoperative venous complications, unlike 4% in the propylene glycol group.
• No significant differences were observed in myoclonic movements, time to loss of eyelid reflex, or blood pressure between the groups.

Conclusions:

• Etomidat-Lipuro, a lipid emulsion formulation of etomidate, offers a significant advantage by reducing injection pain and venous irritation.
• This new formulation improves patient comfort during anesthesia induction.
• The lipid emulsion formulation is a safer alternative to etomidate in propylene glycol for clinical use.